Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
4 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Response to: Correspondence on 'H3.3K27M mutation is not a suitable target for immunotherapy in HLA-A2+ patients with diffuse midline glioma' by Chheda et al.
J Immunother Cancer. 2023 Mar;11(3):e006784. doi: 10.1136/jitc-2023-006784.
J Immunother Cancer. 2023.
PMID: 36918223
Free PMC article.
No abstract available.
Targeting the recurrent Rac1P29S neoepitope in melanoma with heterologous high-affinity T cell receptors.
Immisch L, Papafotiou G, Gallarín Delgado N, Scheuplein V, Paschen A, Blankenstein T, Willimsky G.
Immisch L, et al.
Front Immunol. 2023 Feb 16;14:1119498. doi: 10.3389/fimmu.2023.1119498. eCollection 2023.
Front Immunol. 2023.
PMID: 36875127
Free PMC article.
Item in Clipboard
H3.3K27M mutation is not a suitable target for immunotherapy in HLA-A2+ patients with diffuse midline glioma.
Immisch L, Papafotiou G, Popp O, Mertins P, Blankenstein T, Willimsky G.
Immisch L, et al.
J Immunother Cancer. 2022 Oct;10(10):e005535. doi: 10.1136/jitc-2022-005535.
J Immunother Cancer. 2022.
PMID: 36302563
Free PMC article.
Item in Clipboard
In vitro proteasome processing of neo-splicetopes does not predict their presentation in vivo.
Willimsky G, Beier C, Immisch L, Papafotiou G, Scheuplein V, Goede A, Holzhütter HG, Blankenstein T, Kloetzel PM.
Willimsky G, et al. Among authors: immisch l.
Elife. 2021 Apr 20;10:e62019. doi: 10.7554/eLife.62019.
Elife. 2021.
PMID: 33875134
Free PMC article.
Item in Clipboard
Cite
Cite